JAK1 and Parkinson disease: Recent studies show that α-synuclein can activate the JAK-STAT pathway in microglia and macrophages of a model of Parkinson's disease, while the JAK1/2 inhibitor, AZD1480, attenuates the degeneration of dopaminergic neurons (Qin et al. 2016).